
Regencell Bioscience (RGC) | Stock Overview & Key Data
Regencell Bioscience Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $950.00 on May 30, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
---|---|---|---|---|---|---|---|---|---|
Regencell Bioscience RGC | 7.35B Mid-cap | -1.69% | -77.11% | -50.00% | 190.00% | 200.83% | 334.50% | -57.24% | 41.52% |
Zoetis ZTS | 68.99B Large-cap | -1.33% | -6.84% | 3.69% | -6.83% | -4.70% | -13.45% | -11.22% | 7.12% |
Haleon Plc - ADR HLN | 44.30B Large-cap | -3.61% | -8.13% | -5.79% | 3.90% | 1.69% | 7.63% | 29.42% | 29.42% |
Elanco Animal Health ELAN | 7.43B Mid-cap | -0.81% | 10.88% | 74.29% | 22.76% | 22.66% | 17.61% | -27.55% | -36.58% |
Lantheus Holdings LNTH | 5.15B Mid-cap | -13.69% | -11.15% | -30.25% | -25.38% | -20.97% | -36.98% | 7.19% | 366.12% |
Alkermes plc ALKS | 4.76B Mid-cap | -3.50% | -0.38% | 8.22% | -2.92% | 1.63% | 18.24% | 1.87% | 48.36% |
Ownership & Short Interest
Regencell Bioscience Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Regencell Bioscience would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is RGC's 52-week high and low?
- In the last 52 weeks, Regencell Bioscience reached a high of $83.60 (on June 16, 2025) and a low of $0.08 (on N/A).
- What is the market cap and P/E ratio for RGC?
- Curious about Regencell Bioscience's size and valuation? Its market capitalization stands at 7.35B. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is N/A.
- Does RGC pay dividends? If so, what's the yield?
- As for dividends, Regencell Bioscience isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Regencell Bioscience's main competitors or similar companies to consider before investing?
When looking at Regencell Bioscience, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS68.99B Healthcare Drug Manufacturers - Specialty & Generic -13.45% -11.22% Haleon Plc - ADR
HLN44.30B Healthcare Drug Manufacturers - Specialty & Generic 7.63% 29.42% Elanco Animal Health
ELAN7.43B Healthcare Drug Manufacturers - Specialty & Generic 17.61% -27.55% Lantheus Holdings
LNTH5.15B Healthcare Drug Manufacturers - Specialty & Generic -36.98% 7.19% Alkermes plc
ALKS4.76B Healthcare Drug Manufacturers - Specialty & Generic 18.24% 1.87% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Regencell Bioscience Holdings Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Regencell Bioscience's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -43.18%, the Debt to Equity ratio from the most recent quarter is 1.04, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for RGC?
- Looking at Regencell Bioscience's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of RGC stock is held by insiders and institutions?
- Wondering who owns Regencell Bioscience stock? Company insiders (like executives and directors) hold about 93.84% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.07%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.